Anokion
Dr. Grebe joined Anokion in 2019 bringing over 20 years of experience in immunological, clinical and translational research. Most recently she served as Vice President, Clinical & Translational Development at Anokion where she functioned as clinical development lead for the celiac and multiple sclerosis ph1 trials. Throughout her career she has led and supported translational teams from discovery through phase 3b/IV across of range of small molecule and biologic programs for gastroenterology, rheumatology and dermatology indications. Prior to joining Anokion, Dr. Grebe spent more than a decade in positions of increasing responsibility at Abbvie where she led the clinical translational strategy for multiple programs in the Immunology pipeline, including Skyrizi. Dr. Grebe earned a B.S. in Microbiology and Cell Science from the University of Florida, a Ph.D. in Microbiology and Immunology from the University of Colorado Health Science Center and completed a postdoctoral fellowship in the Laboratory of Viral Disease at the National Institutes of Health.
This person is not in any offices
Anokion
1 followers
Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes.